{"protocolSection": {"identificationModule": {"nctId": "NCT00500539", "orgStudyIdInfo": {"id": "CIGE025C2303"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.", "officialTitle": "An Open Label, Single Arm Study to Assess the Safety and Immunogenicity of Omalizumab Liquid Administered Subcutaneously to Male and Female Adolescents and Adults With Persistent Allergic Asthma"}, "statusModule": {"statusVerifiedDate": "2011-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-07"}, "primaryCompletionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-07-11", "studyFirstSubmitQcDate": "2007-07-11", "studyFirstPostDateStruct": {"date": "2007-07-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-11-17", "resultsFirstSubmitQcDate": "2011-03-30", "resultsFirstPostDateStruct": {"date": "2011-04-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-05-31", "lastUpdatePostDateStruct": {"date": "2011-06-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "external affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}, "collaborators": [{"name": "Genentech, Inc.", "class": "INDUSTRY"}, {"name": "Tanox", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "The primary objective of this study is to assess the immunogenic potential of the liquid formulation of omalizumab administered over a period of 6 months in moderate to severe persistent allergic asthma patients 12 years of age or older, with no previous exposure to the drug (omalizumab na\u00efve patients). The secondary objective of this study is to assess the safety of the liquid formulation of omalizumab in the same patients."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "omalizumab", "safety", "allergic asthma", "adolescents"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 155, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "omalizumab", "description": "The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe."}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Number of Participants With Confirmed Positive Human Antihuman Antibody (HAHA) Results at the End of the 16-week Follow-up Period", "description": "An assessment of the immunogenic potential of omalizumab liquid was a primary objective of the study, and was based on the results of the human anti-human antibody (HAHA) assays at the end of the follow-up period. A participant was considered potentially HAHA positive if either Fab or Fc was more than 2.0 titer. All values more than 2.0 titer were re-assayed to obtain a confirmatory result. Confirmatory results were used to determine those participants who were HAHA positive.", "timeFrame": "16 weeks after last dose"}], "secondaryOutcomes": [{"measure": "Number of Participants Who Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Treatment Period", "description": "The assessment of safety was based on the number of patients with AEs (mild, moderate and severe) and SAEs. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening, causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above. The duration of the treatment period was 24 weeks, but patients were followed for an additional 4 weeks, so that the total duration of the treatment period for purposes of AE reporting was 28 weeks.", "timeFrame": "24 weeks treatment period + 4 weeks for following up participants"}, {"measure": "Number of Participants Who Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Follow-up Period", "description": "The assessment of safety was based on the number of patients with AEs (mild, moderate and severe) and SAEs. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening, causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above. The duration of the follow-up period was 16 weeks, but for purposes of AE reporting the follow-up period was 12 weeks (as the first 4 weeks of follow-up were included in the treatment period).", "timeFrame": "Last 12 weeks of the follow-up period (initial 4 weeks of the follow-up period were included in the treatment period for AE reporting)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients 12 years old or above with moderate to severe allergic asthma\n* Body weight greater than 30kg and less than 150 kg and total serum IgE level greater than 30 to less than 700 IU/ml\n* Diagnosis of allergic asthma greater than 1 year duration, according to the American Thoracic Society criteria (14) and at screening, a history consistent with clinical features of moderate to severe persistent asthma.\n* Positive skin prick test (diameter of wheel is greater than 3mm) to at least one perennial allergen within the previous one year to visit 1, to which the patient will be exposed on a regular basis (most days) for the duration of the study.\n* No clinically significant asthma exacerbations that required treatment with systemic corticosteroids during the four weeks immediately prior to screening visit (Visit 1) and during screening period (between Visit 1 and 2)\n* Demonstrated evidence of inadequate asthma symptom control, despite treatment with ICS according to clinical features of moderate to severe persistent asthma.\n\nExclusion Criteria:\n\n* Previous exposure to omalizumab\n* Previous exposure to other humanized proteins or monoclonal antibodies\n* Known HAHA to other monoclonal antibodies\n* History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures\n* Known hypersensitivity to any ingredients, including excipients of the study medication or drugs related to omalizumab (e.g. monoclonal antibodies, polyclonal gamma globulin)\n* Active lung disease other than allergic asthma (e.g. cystic fibrosis, bronchiectasis)\n* Elevated serum IgE levels for reasons other than allergy (e.g. parasite infections, hyperimmunoglobulin E syndrome, Wiskott-Aldrich Syndrome or allergic bronchopulmonary aspergillosis)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jose Bardelas, MD", "affiliation": "Allergy and Asthma center of North Carolina, PA, High Point, NC 27262", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Allergy & Immunology Associates, Ltd", "city": "Scottsdale,", "state": "Arizona", "zip": "AZ 85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "California Allergy and Asthma Medical Group", "city": "Palmdale", "state": "California", "zip": "CA 93551", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Allergy Associates Medical Group, Inc,", "city": "San Diego", "state": "California", "zip": "CA 92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Bensch Research Associates", "city": "Stockton", "state": "California", "zip": "CA 95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "1st Allergy and Clinical Research Center", "city": "Centennial", "state": "Colorado", "zip": "CO 80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Innovative Research of West Florida, Inc.", "city": "Largo", "state": "Florida", "zip": "FL 33770", "country": "United States", "geoPoint": {"lat": 27.90979, "lon": -82.78842}}, {"facility": "Georgia Pollen", "city": "Albany", "state": "Georgia", "zip": "GA 31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Kansas City Allergy & Asthma", "city": "Overland Park", "state": "Kansas", "zip": "66210", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "Asthma and Allergy Specialists, PA", "city": "Minneapolis", "state": "Minnesota", "zip": "MN 55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": ": The Clinical Research Center, LLC", "city": "St. Louis", "state": "Missouri", "zip": "MO 63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Allergy, Asthma and Clinical Immunology", "city": "Brick", "state": "New Jersey", "zip": "NJ 08724", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"facility": "Asthma & Allergy Research of NJ, Inc.", "city": "Mt. Laurel", "state": "New Jersey", "zip": "NJ 08054", "country": "United States", "geoPoint": {"lat": 39.934, "lon": -74.891}}, {"facility": "Nassau Chest Pysicians, PC", "city": "Massapequa", "state": "New York", "zip": "NY 11758", "country": "United States", "geoPoint": {"lat": 40.68066, "lon": -73.47429}}, {"facility": "Allergy and Asthma Center of NC, PA", "city": "High Point", "state": "North Carolina", "zip": "NC 27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Allergy Center at Brookstone", "city": "Columbus", "state": "Ohio", "zip": "OH 31904", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Toledo Center for Clinical Research", "city": "Sylvania", "state": "Ohio", "zip": "OH 43650", "country": "United States", "geoPoint": {"lat": 41.71894, "lon": -83.71299}}, {"facility": "Asthma and Allergy Center", "city": "Toledo", "state": "Ohio", "zip": "OH 43617", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "The Corvallis Clinic, PC", "city": "Corvallis", "state": "Oregon", "zip": "OR 97330", "country": "United States", "geoPoint": {"lat": 44.56457, "lon": -123.26204}}, {"facility": "Allergy, Asthma & Dermatology Research Center", "city": "Lake Oswego", "state": "Oregon", "zip": "OR97037", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}, {"facility": "Clinical Research Institute of Southern Oregon, PC", "city": "Medford", "state": "Oregon", "zip": "OR 97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Allergy & Asthma Specialists, PC", "city": "Blue Bell", "state": "Pennsylvania", "zip": "PA 19422", "country": "United States", "geoPoint": {"lat": 40.15233, "lon": -75.26629}}, {"facility": "Asthma Allergy & Pulmonary Associates, PC", "city": "Philadelphia", "state": "Pennsylvania", "zip": "PA 19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "AAPRI Clinical Research Institute", "city": "Providence,", "state": "Rhode Island", "zip": "RI 02906", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "North Texas Institute for Clinical Trials", "city": "Fort Worth", "state": "Texas", "zip": "TX 76132", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Allergy and Asthma Associates", "city": "Houston,", "state": "Texas", "zip": "TX 77054", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Clinical Trials of North Houston", "city": "Houston", "state": "Texas", "zip": "TX 77070", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site,", "city": "Buenos Aires,", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site,", "city": "Corrientes,", "country": "Argentina", "geoPoint": {"lat": -27.4806, "lon": -58.8341}}, {"facility": "Novartis Investigative Site,", "city": "Mendoza", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Novartis Investigator site", "city": "Nuremberg", "country": "Germany", "geoPoint": {"lat": 49.45421, "lon": 11.07752}}]}, "referencesModule": {"references": [{"pmid": "24028677", "type": "DERIVED", "citation": "Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2014 Jan;30(1):59-66. doi: 10.1185/03007995.2013.844115. Epub 2013 Oct 1."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Omalizumab", "description": "The determined dose was injected subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used."}], "periods": [{"title": "Treatment Period (24 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "155"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "140"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}]}]}, {"title": "Follow-up Period (16 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Participants could discontinue study drug and still enter the follow-up period.", "numSubjects": "148"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "136"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Missing", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Omalizumab", "description": "The determined dose was injected subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "155"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "13"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "135"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "7"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.7", "spread": "14.32"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "95"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "60"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Number of Participants With Confirmed Positive Human Antihuman Antibody (HAHA) Results at the End of the 16-week Follow-up Period", "description": "An assessment of the immunogenic potential of omalizumab liquid was a primary objective of the study, and was based on the results of the human anti-human antibody (HAHA) assays at the end of the follow-up period. A participant was considered potentially HAHA positive if either Fab or Fc was more than 2.0 titer. All values more than 2.0 titer were re-assayed to obtain a confirmatory result. Confirmatory results were used to determine those participants who were HAHA positive.", "populationDescription": "The Safety Population consisted of all patients that received any part of a dose of study drug and had any post-baseline assessment, whether scheduled or not. The analysis was done on total number of patients who had follow-up HAHA sample taken.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "16 weeks after last dose", "groups": [{"id": "OG000", "title": "Follow-up Period", "description": "Participants were evaluated at 16 weeks after the last dose of study drug."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}]}], "classes": [{"title": "Fab HAHA Positive - Negative at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Fab HAHA Positive - Positive at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Fab HAHA Positive - Missing at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Fc HAHA Positive - Negative at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Fc HAHA Positive - Positive at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Fc HAHA Positive - Missing at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Fab and/or Fc HAHA Positive - Fab and Fc HAHA -Ve", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Missing at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Treatment Period", "description": "The assessment of safety was based on the number of patients with AEs (mild, moderate and severe) and SAEs. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening, causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above. The duration of the treatment period was 24 weeks, but patients were followed for an additional 4 weeks, so that the total duration of the treatment period for purposes of AE reporting was 28 weeks.", "populationDescription": "The safety population consisted of all patients that received any part of a dose of study drug and had any post-baseline assessment, whether scheduled or not.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-12", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "24 weeks treatment period + 4 weeks for following up participants", "groups": [{"id": "OG000", "title": "Treatment Period", "description": "The determined dose was injected subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}]}], "classes": [{"title": "Participants with AEs during the treatment period", "categories": [{"measurements": [{"groupId": "OG000", "value": "124"}]}]}, {"title": "Mild AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}, {"title": "Moderate AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}]}]}, {"title": "Severe AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}, {"title": "AEs suspected to be related to study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}]}]}, {"title": "AEs not suspected to be related to study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "102"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Serious Adverse Events (SAEs)", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}]}]}, {"title": "Discontinued due to Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Discontinued due to Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Discontinued due to non-serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Follow-up Period", "description": "The assessment of safety was based on the number of patients with AEs (mild, moderate and severe) and SAEs. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening, causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above. The duration of the follow-up period was 16 weeks, but for purposes of AE reporting the follow-up period was 12 weeks (as the first 4 weeks of follow-up were included in the treatment period).", "populationDescription": "The safety population consisted of all patients that received any part of a dose of study drug and had any post-baseline assessment, whether scheduled or not.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-12", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Last 12 weeks of the follow-up period (initial 4 weeks of the follow-up period were included in the treatment period for AE reporting)", "groups": [{"id": "OG000", "title": "Follow-up Period", "description": "Participants were assessed at 16 weeks after the last dose of study drug"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}]}], "classes": [{"title": "Participants with AEs during the follow-up period", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}]}]}, {"title": "Mild AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "Moderate AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}]}]}, {"title": "Severe AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "AEs suspected to be related to study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "AEs not suspected to be related to study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Serious adverse events (SAEs)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Discontinued due to Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Discontinued due to Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Discontinued due to non-serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Treatment period AEs were collected from first treatment dose until 28 days post last treatment dose (28 weeks total). Follow-up period AEs defined as AEs that began after 28 days post last treatment dose until the end of the follow-up (12 weeks total).", "description": "The safety population consisted of all patients that received any part of a dose of study drug and had any post-baseline assessment, whether scheduled or not.", "eventGroups": [{"id": "EG000", "title": "Omalizumab Treatment Period", "description": "The determined dose was injected subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used.", "seriousNumAffected": 14, "seriousNumAtRisk": 155, "otherNumAffected": 74, "otherNumAtRisk": 155}, {"id": "EG001", "title": "Omalizumab Follow up Period", "description": "Participants were assessed at 16 weeks after the last dose of study drug", "seriousNumAffected": 1, "seriousNumAtRisk": 148, "otherNumAffected": 34, "otherNumAtRisk": 148}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Enteritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Bronchiectasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Cartilage injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Post procedural swelling", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 148}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Laryngeal inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}], "otherEvents": [{"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 148}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 148}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 148}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 148}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 148}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 155}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 148}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial; or the publication of the trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}